November 15, 2012, Billerica, MA - EMD Millipore, the life science division of Merck KGaA of Darmstadt, Germany, today announced the launch of Eshmuno® CPX media, a strong cation exchanger optimized for intermediate or polishing purification of monoclonal antibodies. Built on EMD Millipore’s proven Eshmuno® resin technology, the new media offers high aggregate removal efficiency and high dynamic binding capacity, supporting highly productive downstream bioprocessing.
The primary challenge for intermediate purification and polishing is the selectivity to remove impurities similar to the target molecule such as aggregates and host cell proteins, even at high loading levels. Eshmuno® CPX media offers these features for different types of biomolecules.
Eshmuno® CPX media was specifically built on EMD Millipore’s proven tentacle technology allowing for a multipoint interaction. This technology in combination with the hydrophilic polyvinylether base bead allows the binding of the target molecule and impurity removal over a wide range of process conditions.
Eshmuno® CPX media is compatible over a wide range of pH conditions, providing excellent process stability against alkaline and acids. It is available in pre-packed, ready-to-use, disposable columns, the ideal tool for performing initial media screening, scaling and optimization studies. The columns can be used with any chromatography system.
“High titers in upstream processing create a bottleneck in downstream processing, slowing down the production process,” said Jonas Anders, Global Marketing Director, Purification Chromatography. “As a result, there is a need for highly productive and reliable purification technologies. Eshmuno® CPX media is the first member of an expanded, novel high-resolution platform designed to meet the needs for highly productive downstream bioprocessing applications.”
About EMD Millipore
EMD Millipore is the life science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the life science tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.
Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries and 2011 revenues of EUR 2.4 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.
